Neurocrine Biosciences (NASDAQ:NBIX) Earns "Outperform" Rating from Wedbush

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report)'s stock had its "outperform" rating restated by analysts at Wedbush in a research report issued to clients and investors on Tuesday,RTT News reports. Wedbush also issued estimates for Neurocrine Biosciences' Q2 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.34 EPS, Q4 2025 earnings at $1.38 EPS, FY2025 earnings at $3.92 EPS, Q1 2026 earnings at $1.10 EPS, Q2 2026 earnings at $1.41 EPS, Q3 2026 earnings at $1.58 EPS, Q4 2026 earnings at $1.68 EPS, FY2026 earnings at $5.77 EPS, FY2027 earnings at $8.90 EPS, FY2028 earnings at $10.49 EPS and FY2029 earnings at $13.78 EPS.

NBIX has been the topic of several other reports. Evercore ISI dropped their price objective on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. William Blair reissued an "outperform" rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Needham & Company LLC raised their price target on Neurocrine Biosciences from $138.00 to $139.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Morgan Stanley reaffirmed an "overweight" rating and set a $150.00 target price (down previously from $185.00) on shares of Neurocrine Biosciences in a report on Friday, March 7th. Finally, StockNews.com downgraded Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research report on Thursday, March 20th. Three investment analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. Based on data from MarketBeat, Neurocrine Biosciences has a consensus rating of "Moderate Buy" and an average target price of $162.00.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX traded down $1.81 during trading on Tuesday, reaching $115.71. 1,319,681 shares of the stock were exchanged, compared to its average volume of 1,115,471. The stock has a fifty day moving average of $106.23 and a two-hundred day moving average of $121.85. Neurocrine Biosciences has a 1-year low of $84.23 and a 1-year high of $157.98. The firm has a market cap of $11.45 billion, a price-to-earnings ratio of 35.17, a price-to-earnings-growth ratio of 0.77 and a beta of 0.26.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). The firm had revenue of $572.60 million during the quarter, compared to the consensus estimate of $587.06 million. Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. The company's revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.20 earnings per share. Sell-side analysts forecast that Neurocrine Biosciences will post 4.28 EPS for the current year.

Neurocrine Biosciences announced that its board has authorized a share buyback program on Friday, February 21st that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 4.2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board of directors believes its stock is undervalued.

Insider Transactions at Neurocrine Biosciences

In other news, CEO Kyle Gano sold 980 shares of the company's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $118.39, for a total transaction of $116,022.20. Following the transaction, the chief executive officer now owns 137,658 shares in the company, valued at $16,297,330.62. This represents a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Julie Cooke sold 700 shares of the business's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $118.28, for a total value of $82,796.00. Following the sale, the insider now owns 18,831 shares in the company, valued at approximately $2,227,330.68. The trade was a 3.58 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,907 shares of company stock worth $4,935,982. 4.80% of the stock is currently owned by company insiders.

Institutional Trading of Neurocrine Biosciences

A number of hedge funds have recently modified their holdings of NBIX. OneDigital Investment Advisors LLC raised its position in shares of Neurocrine Biosciences by 2.1% during the 4th quarter. OneDigital Investment Advisors LLC now owns 4,215 shares of the company's stock worth $575,000 after purchasing an additional 87 shares during the last quarter. HighPoint Advisor Group LLC lifted its position in Neurocrine Biosciences by 4.1% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,446 shares of the company's stock valued at $334,000 after buying an additional 96 shares during the last quarter. Huntington National Bank boosted its position in shares of Neurocrine Biosciences by 73.5% during the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock worth $31,000 after purchasing an additional 97 shares during the period. Louisiana State Employees Retirement System raised its holdings in shares of Neurocrine Biosciences by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 28,100 shares of the company's stock valued at $3,836,000 after buying an additional 100 shares during the period. Finally, Utah Retirement Systems lifted its position in shares of Neurocrine Biosciences by 0.6% during the fourth quarter. Utah Retirement Systems now owns 16,583 shares of the company's stock worth $2,264,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.